SEOM–TTCC clinical guideline for nasopharyngeal carcinoma (update 2025)

Clinical & Translational Oncology 2026 Open access

Read full text
Authors: Antonio Rueda Domínguez, Beatriz Cirauqui, Almudena García Castaño, R. Álvarez Cabellos, Alberto Carral Maseda, Beatriz Castelo Fernández, Leticia Iglesias Rey, Jordi Rubió‑Casadevall, Virginia Arrazubi, Ricard Mesía
DOI: 10.1007/s12094-026-04252-5
Cited by: 4
References: 77

Abstract

Nasopharyngeal carcinoma is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy is the cornerstone of locoregional treatment of non-disseminated disease and, in combination with chemotherapy, improves survival rates. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy, and patients may achieve a long survival time. In these guidelines (updated in 2025), we summarize current evidence and available therapies for the medical management of advanced nasopharyngeal carcinoma.

Fields of Study & Subjects

Head and Neck Cancer Studies Head and Neck Surgical Oncology Oral Health Pathology and Treatment

Publication details

Journal / source
Clinical & Translational Oncology
Publisher
Springer Science and Business Media LLC
Volume
28
Issue
4
Pages
1151–1164
Publication date
17 February 2026
Language
EN